Genomtec S.A.
GMT.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.69 | 0.35 | -0.20 | 0.31 |
| FCF Yield | -6.46% | -8.69% | -7.46% | -7.53% |
| EV / EBITDA | -11.57 | -16.76 | -9.67 | -11.65 |
| Quality | ||||
| ROIC | -85.76% | -63.55% | -115.37% | -408.81% |
| Gross Margin | 100.00% | -79,300.00% | -2,042.50% | -171.69% |
| Cash Conversion Ratio | 0.60 | 0.88 | 0.32 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.76% | -83.41% | 25.99% | 12.77% |
| Free Cash Flow Growth | 40.98% | -41.37% | -41.44% | -117.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 0.28 | 0.17 | -0.06 |
| Interest Coverage | -82.50 | -36.98 | -40.93 | -376.43 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 8.16 | 3.04 |
| Cash Conversion Cycle | 640,452.50 | 298.34 | 5,912.46 | 29.80 |